PMID- 10965814
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20061115
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 19
IP  - 2
DP  - 2000 Jun
TI  - Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA 
      repair capacity in breast cancer families.
PG  - 169-73
AB  - In vitro mutagen susceptibility has been observed as a predictor of cancer risk. 
      To evaluate susceptibility to mutagen, we have studied the response to in vitro 
      bleomycin (BLM) treatment in cultured peripheral blood lymphocytes (PBL) of 9 
      breast cancer families (BCFs). Eleven breast cancer patients (BCPs) and 36 
      healthy blood relatives (HBRs) from BCFs were included in the study. Data were 
      compared with 22 healthy control women. The frequencies of chromosomal 
      aberrations were evaluated after exposure to BLM in the last five hours. Mean 
      frequency of BLM-induced chromosomal aberrations per cell (CA) observed among 
      BCPs was significantly higher as compared to their HBRs as well as control 
      subjects. Moreover, mean BLM-induced CA/cell value observed for HBRs was also 
      significantly higher than that of control subjects. In comparison to controls, it 
      was observed that there was four times more cancer risk in BCPs (OR=4.148, 95% 
      CI=5.83-687.46) and 2.5 times more cancer risk in HBRs (OR=2.67, 95% 
      CI=5.31-39.25). Lymphocytes from 90% of BCPs and 69% of HBRs were found to be 
      sensitive to BLM (using a cutoff value = controls group mean + 1 SD). Thus, 
      lymphocytes of BCPs and their HBRs were more sensitive to BLM exposure as 
      compared to controls. Our finding indicated inefficient DNA repair capacity in 
      BCFs. The HBRs in BCFs, having increased BLM-sensitivity, may be at higher risk 
      to develop a similar cancer.
FAU - Roy, S K
AU  - Roy SK
AD  - Cell Biology Division, The Gujarat Cancer Society, Asarwa, Ahmedabad, India.
FAU - Trivedi, A H
AU  - Trivedi AH
FAU - Bakshi, S R
AU  - Bakshi SR
FAU - Patel, S J
AU  - Patel SJ
FAU - Shukla, P H
AU  - Shukla PH
FAU - Bhatavdekar, J M
AU  - Bhatavdekar JM
FAU - Patel, D D
AU  - Patel DD
FAU - Shah, P M
AU  - Shah PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (DNA, Neoplasm)
RN  - 11056-06-7 (Bleomycin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibiotics, Antineoplastic/*pharmacology
MH  - Bleomycin/*pharmacology
MH  - Breast Neoplasms/blood/*genetics/metabolism
MH  - Chromatids/drug effects/metabolism
MH  - Chromosome Aberrations
MH  - Chromosome Disorders
MH  - Chromosomes, Human/drug effects
MH  - DNA Damage/*drug effects
MH  - *DNA Repair
MH  - DNA, Neoplasm/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Lymphocytes/drug effects
MH  - Metaphase/genetics
MH  - Middle Aged
MH  - Sensitivity and Specificity
EDAT- 2000/08/31 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/31 11:00
PHST- 2000/08/31 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/31 11:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 2000 Jun;19(2):169-73.